ZEUS Is Officially America's Most Powerful Laser, With 2-Petawatt Blast
The ZEUS laser, tucked away (as much as a giant laser can be) at the University of Michigan, just cranked out a pulse that makes it the most powerful laser beam in the country.
ZEUS' peak power topped out at 2 petawatts, or a staggering 2 quadrillion watts, roughly 100 times the entire planet's power output. Of course, that level of energy is fleeting; the pulse lasts just 25 quintillionths of a second—just enough time for researchers to do some pretty revolutionary science.
'This milestone marks the beginning of experiments that move into unexplored territory for American high field science,' said Karl Krushelnick, director of the Gérard Mourou Center for Ultrafast Optical Science, where ZEUS is housed, in a Michigan release.
ZEUS is short for Zettawatt Equivalent Ultrashort laser pulse System, and its power (at the risk of blasphemy) rivals that of the king of the Greek gods, who famously wields a lightning bolt as a symbol of his power. ZEUS is funded by the National Science Foundation, and scientists from around the world can apply to run experiments there—similar to the Linac Coherent Light Source II (or LCLS-II) at the SLAC National Accelerator Laboratory. Like LCLS-II—whose domain ranges from understanding photosynthesis and the cores of stars—the applications of ZEUS' laser range from plasma and quantum physics to medical imaging, particle acceleration, and materials research.
'The energy of the individual photons in a pulse from LCLS is about 20,000 times greater than the photons from the ZEUS laser—but the peak power is 100,000 times lower,' Krushelnick told Gizmodo in an email. Krushelnick added that the use cases of ZEUS are manifold, but measuring physics at extreme intensities, the development of new radiation sources, laboratory astrophysics and imaging small-scale materials are a few of its principal scientific uses.
Franklin Dollar, a physicist at UC Irvine, will run the first 2-petawatt user experiment, aiming to produce electron beams with energies comparable to those from long particle accelerators. Should he and his team succeed, the electron beam energies will be between 5 and 10 times higher than any beams ZEUS has yet produced. ZEUS will accelerate electrons using wakefield acceleration, by which electrons essentially surf on plasma to accelerate to extremely high speeds.
'The quest for higher peak power lasers enables studies of the fundamental nature of light in the limit of extremely high instantaneous electromagnetic fields,' said Vyacheslav Lukin, program director in the NSF Division of Physics, which oversees the ZEUS project, in an email to Gizmodo. 'Just as ocean waves begin to break and foam as they get higher, electromagnetic waves act differently when the light becomes very intense and the electromagnetic field gets extremely strong.'
The beam isn't just powerful—it's quite large. At its biggest, the laser pulse is one foot (0.3 meters) across and several feet long, according to the Michigan release. But the pulse is ultimately focused down to just 0.8 microns wide, to maximize the number of laser pulses available for experiments on ZEUS.
But the big show is set for later this year, when the facility will get a titanium-infused sapphire crystal that will increase the laser's power to three petawatts. The crystal took nearly five years to manufacture and is about 7 inches (0.18 m) across. ZEUS' electrons will smash into laser pulses from the opposite direction, increasing the experiment's pulse to essentially zettawatt-scale in the frame of reference of the particle beam.
About 15 months of user experiments have already been conducted on ZEUS' single petawatt laser, but now the facility is capable of hitting much more powerful energy pulses. With the new and improved laser, the team can better interrogate some of the universe's most fundamental physics, with implications across the sciences.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
39 minutes ago
- Medscape
Fast Five Quiz: Low-Risk Myelodysplastic Syndrome
Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematopoietic stem cell disorders, each with varying levels of prognosis. Risk stratification is an important component of MDS; however, even lower-risk variants require a nuanced approach to management, and certain factors can further affect patient risk after diagnosis. What do you know about low-risk MDS? Check your knowledge with this quick quiz. Among the gene mutations identified that can influence the prognosis in MDS, SF3B1 mutation is strongly associated with favorable clinical outcomes. Other mutations such as such as TP53 , ASXL1 , EZH2 , ETV6 , and RUNX1 typically lead to poorer clinical outcomes. The National Comprehensive Care Network (NCCN) notes that combining analysis of these mutations in MDS with International Prognostic Scoring System (IPSS) can improve risk stratification beyond the strengths of the IPSS alone, which is standard practice in some treatment centers. Learn more about cytogenic studies for MDS. Data have shown that hypocellular bone marrow is one of several factors that predict good response to IST in patients with lower-risk MDS. The NCCN specifically recommends IST in select patients, generally those 'aged ≤60 years and with ≤5% marrow blasts, or those with hypocellular marrows, PNH clone positivity, or STAT-3 mutant cytotoxic T-cell clones.' Other factors associated with predicted benefit from IST include presence of dysplasia, young age (< 60 years), presence of HLA DR15, female sex, absence of ring sideroblasts, presence of trisomy 8, and relatively short duration of transfusion need. Learn more about hypocellular marrow in MDS. A study of patients with very low- and low-risk MDS found that mutations in three genes, IDH1 , IDH2 , and NPM1 , are more common among those patients with direct transformation to AML. NPM1 mutations are the most frequently-seen mutation in AML and are found in approximately 30%-35% of cases among adults. Mutations in ASXL1 , CBL , and TP53 were found to be associated with progression to higher-risk MDS but not with transformation to AML. Learn more about cytogenetics in MDS. According to a review published in JAMA , the median survival time for patients with low and very low risk MDS is 5.3 years and 8.8 years, respectively. This is consistent with other recent data. Collected data from the same JAMA review indicated that the median age for MDS diagnosis is approximately 70 years and is more common in males; chemotherapy and radiation therapy exposure are also reported significant risk factors. Further, the IPSS, revised-IPSS, and WHO classification-based prognostic scoring system are the most frequently used scoring systems for MDS risk. Learn more about MDS risk staging. Due to longer survival, patients with low-risk MDS might be given multiple red blood cell transfusions as part of their management (which could potentially lead to iron overload). To decrease iron overload, the NCCN recommends consideration of daily iron chelation with subcutaneous deferoxamine or oral deferasirox after > 20-30 transfusions. This approach is especially recommended for patients with lower-risk MDS or those who are potential candidates for transplantation. Learn more about iron chelation in MDS. Editor's Note: This article was created using several editorial tools, including generative AI models, as part of the process. Human review and editing of this content were performed prior to publication.
CNET
an hour ago
- CNET
Anyone Can Now Access the Largest Space Map Ever Created, Here's How
If you've ever wanted a better look at deep space, you now have your chance. A treasure trove of data collected by the James Webb Space Telescope is now available for public consumption. Included with the data is an interactive map that contains nearly 800,000 galaxies and various filters so you can view them in different ways. The data was made available starting on June 5 by the Cosmic Evolution Survey out of Caltech. It consists of survey data that mapped out 0.54 square degrees of the sky. For reference, if you take a look at this month's strawberry moon, the amount of sky that was mapped is equivalent to about three full moons side by side. The total size of all the map data is about 1.5 TB. Read more: Coolest Space Photos of 2025 Will Fill You With Cosmic Wonder Included in the map are galaxies and stars that are 13.5 billion years old, which means it provides the best look into the early universe that science has offered so far. NASA estimates that the universe is 13.8 billion years old, so those galaxies and stars are positively ancient. In all, there are galaxies and stars in the data that cover about 98% of the known universe's history. That makes it bigger than the largest Milky Way galaxy map ever created, which still only covers a small slice of the galaxy's overall layout. However, the Milky Way galaxy map is still larger in terms of data, as that map is over 500 TB in size. Researchers mapped the sky with the JWST's Near Infrared Camera and 0.2 square degrees of the sky with the Mid Infrared Instrument. In total, there's about 1.5 TB worth of data to sift through. Arguably the coolest part of the info dump is the interactive map, which loads in a web browser and allows users to move around and see everything that was included. Clicking on a point of interest shows you data about the star or galaxy you selected. COSMOS2025 Using the interactive map viewer Curious individuals can check out the project's map use the map, you simply have to follow the link and click the "check it out!" button. Once the map loads, you'll see a square-ish image that contains over 700,000 galaxies and other objects. Once you load the map, the best way to view it is using the layers and filters in the top right corner. The first box contains views, including NIRCam RGB and several other views. The second box breaks up the image into tiles. These tiles are how the image was mapped, so you can see which James Webb instrument was used to capture each segment of the map. For education purposes, the third box is the one to use. These options outline the objects of interest. Clicking on them provides you with a catalog ID — which lets you search for those objects again later — along with the raw images taken of each one and additional data points like light wavelength. The tools in the top left are used for search and configuration, like increasing the brightness and changing the hue to make some objects easier to view. With the controls, your best bet is to just look around and find all the cool stuff. At any point,k you can reset all of the settings by refreshing the browser window. How to access the data The data is accessible in a couple of different ways. The COSMOS2025 project published three research papers on the data they collected. The first is a catalog of everything that was observed. The other two focused on the near infrared imaging and mid infrared imaging used to obtain the data. You can obtain the data by filling out this form. Once done, you'll be able to download the data. It's available as a single, large download or you can download individual tiles if you prefer. There are more advanced instructions available from the COSMOS2025 project website if you need them and more data available here if you want to download it. You may notice that the majority of the map data is in the FITS file format. That's an unusual file format that your standard Photoshop or similar app won't be able to handle very well. Fortunately, NASA has a trustworthy list of FITS image viewers that you can choose from. The data will also be used to help answer questions about the early universe, and all this data being freely available to researchers the world over will help with that.
Bloomberg
2 hours ago
- Bloomberg
Biotech Start-Ups Feel the Pain of Federal Funding Cuts
The Trump administration's attack on the National Institutes of Health is strangling the biotech industry's innovation engine — and it could get much worse. The ongoing, brutal termination of grant funding for academic research has rightfully dominated the headlines. These cuts will eventually become a real problem, as fewer dollars mean fewer discoveries to be pulled from academia and into biotech and pharmaceutical companies.
